[go: up one dir, main page]

WO2009088220A3 - N,n-dimethyl imidodicarbonimidic diamide nicotinate, method for producing the same and pharmaceutical composition comprising the same - Google Patents

N,n-dimethyl imidodicarbonimidic diamide nicotinate, method for producing the same and pharmaceutical composition comprising the same Download PDF

Info

Publication number
WO2009088220A3
WO2009088220A3 PCT/KR2009/000071 KR2009000071W WO2009088220A3 WO 2009088220 A3 WO2009088220 A3 WO 2009088220A3 KR 2009000071 W KR2009000071 W KR 2009000071W WO 2009088220 A3 WO2009088220 A3 WO 2009088220A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
pharmaceutical composition
imidodicarbonimidic diamide
dimethyl imidodicarbonimidic
nicotinate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/000071
Other languages
French (fr)
Korean (ko)
Other versions
WO2009088220A2 (en
Inventor
김성욱
전성수
조영관
구자성
김영웅
김병하
강민석
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanall Pharmaceutical Co Ltd
Original Assignee
Hanall Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Pharmaceutical Co Ltd filed Critical Hanall Pharmaceutical Co Ltd
Publication of WO2009088220A2 publication Critical patent/WO2009088220A2/en
Publication of WO2009088220A3 publication Critical patent/WO2009088220A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein are a novel nicotinic acid salt of N,N-dimethyl imidodicarbonimidic diamide, a preparation method thereof and a pharmaceutical composition comprising the same. More specifically, disclosed herein are the nicotinic acid salt of N,N-dimethyl imidodicarbonimidic diamide, which has improved physical and chemical properties including solubility, stability, non-hygroscopicity and anti-adhesive properties, and low toxicity, and thus is very effective in the prevention and treatment of not only diabetes and its complications in patients with so-called metabolic syndromes, in which diabetes, obesity, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndromes, etc. appear in combination, but also of p53 gene-deficient cancers, muscular pain, muscle cytotoxicity and rhabdomyolysis, as well as the preparation method thereof and the pharmaceutical composition comprising the same.
PCT/KR2009/000071 2008-01-08 2009-01-07 N,n-dimethyl imidodicarbonimidic diamide nicotinate, method for producing the same and pharmaceutical composition comprising the same Ceased WO2009088220A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20080002118 2008-01-08
KR10-2008-0002118 2008-01-08

Publications (2)

Publication Number Publication Date
WO2009088220A2 WO2009088220A2 (en) 2009-07-16
WO2009088220A3 true WO2009088220A3 (en) 2009-09-03

Family

ID=40853597

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/000071 Ceased WO2009088220A2 (en) 2008-01-08 2009-01-07 N,n-dimethyl imidodicarbonimidic diamide nicotinate, method for producing the same and pharmaceutical composition comprising the same

Country Status (2)

Country Link
KR (1) KR101104912B1 (en)
WO (1) WO2009088220A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116887866A (en) 2020-12-03 2023-10-13 巴特尔纪念研究院 Polymer nanoparticle and DNA nanostructure compositions and methods for non-viral delivery
AU2022253899A1 (en) 2021-04-07 2023-10-26 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2357864A1 (en) * 1973-06-01 1974-12-19 Hurka Wilhelm Anti-diabetic agents prepn. - from biguanidine (salt) and nicotinic acid (salt)
US4028402A (en) * 1974-10-11 1977-06-07 Hoffmann-La Roche Inc. Biguanide salts
US4835184A (en) * 1985-07-31 1989-05-30 Albert Rolland Sa Novel pharmaceutical compositions intended to the treatment of neuropathies and promoting the nervous regeneration
US6031004A (en) * 1997-12-08 2000-02-29 Bristol-Myers Squibb Company Salts of metformin and method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2357864A1 (en) * 1973-06-01 1974-12-19 Hurka Wilhelm Anti-diabetic agents prepn. - from biguanidine (salt) and nicotinic acid (salt)
US4028402A (en) * 1974-10-11 1977-06-07 Hoffmann-La Roche Inc. Biguanide salts
US4835184A (en) * 1985-07-31 1989-05-30 Albert Rolland Sa Novel pharmaceutical compositions intended to the treatment of neuropathies and promoting the nervous regeneration
US6031004A (en) * 1997-12-08 2000-02-29 Bristol-Myers Squibb Company Salts of metformin and method

Also Published As

Publication number Publication date
KR20090076827A (en) 2009-07-13
KR101104912B1 (en) 2012-01-12
WO2009088220A2 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
WO2009038396A3 (en) N,n-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same
EP1698624A4 (en) PHENYLPROPANOIC ACID DERIVATIVES
WO2011083999A3 (en) Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient
WO2016105118A3 (en) Biaryl derivative as gpr120 agonist
JP2008521829A5 (en)
JP2008521831A5 (en)
JP2009530399A5 (en)
WO2009088220A3 (en) N,n-dimethyl imidodicarbonimidic diamide nicotinate, method for producing the same and pharmaceutical composition comprising the same
WO2009002427A3 (en) Methods of synthesizing cinacalcet and salts thereof
WO2008040548A3 (en) Treatment for non-alcoholic-steatohepatitis
HK1222658A1 (en) Cyanotriazole compounds
WO2006128056A3 (en) Novel phosphinic acid-containing thyromimetics
WO2010094126A8 (en) Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JO3813B1 (en) Novel fatty acids and their use in conjugation to biomolecules
CY1122742T1 (en) DIARYL DERIVATIVES AS GPR120 COMPETITORS
WO2004113270A3 (en) Propionic acid derivatives useful in the treatment of lipid disorders
WO2009087212A3 (en) Pyridine derivatives
TW200628154A (en) Organic compounds
HK1207860A1 (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
WO2010003624A3 (en) Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP1784388B8 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
WO2006099941A8 (en) Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments
MX2010003603A (en) Method of treating polycystic kidney diseases with ceramide derivatives.
WO2006128055A3 (en) Novel phosphorus-containing thyromimetics
MY139107A (en) Substituted n-cyclohexylimidazolinones, process for their preparation and their use as medicaments.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09701355

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09701355

Country of ref document: EP

Kind code of ref document: A2